HLB BioStep Q1 2026: Revenue Slightly Down, Net Loss Widens; Order Backlog of 24.6B Won

Consolidated revenue: 13,485M KRW (slight decrease from 13,578M in Q4 2025)
Operating loss: 2,611M KRW (vs 2,547M loss)
Net loss: 2,116M KRW (vs 1,834M loss)
Order backlog: 24,648M KRW (efficacy 5,732M, toxicity 12,719M, construction 6,198M)
Cash and equivalents: 28,602M KRW (down from 41,157M)
Capital reserves of 40B KRW transferred to retained earnings (strengthens equity)
Partial conversion of 4th CB (250M KRW) issued 156,445 common shares
Separate: revenue 6,147M, operating loss 2,143M, net loss 1,614M